Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 19/20 | 0.93 |
| ▸ | EGFR | P00533 | 11/20 | 0.93 |
| ▸ | ITK | Q08881 | 6/20 | 0.91 |
| ▸ | LCK | P06239 | 5/20 | 0.91 |
| ▸ | FLT3 | P36888 | 2/20 | 0.71 |
| ▸ | KIT | P10721 | 1/20 | 0.71 |
| ▸ | JAK3 | P52333 | 2/20 | 0.70 |
| ▸ | TEC | P42680 | 3/20 | 0.69 |
| ▸ | BMX | P51813 | 3/20 | 0.69 |
| ▸ | TXK | P42681 | 2/20 | 0.69 |
| ▸ | LYN | P07948 | 2/20 | 0.69 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.69 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.69 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.69 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.69 |
| ▸ | LATS1 | O95835 | 1/20 | 0.69 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.69 |
| ▸ | ABL1 | P00519 | 1/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.69 |
| ▸ | FYN | P06241 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL408535 | 1.00 | BTK (0.93) | BTKEGFRITKLCKFLT3 | |
| SCHEMBL722563 | 1.00 | BTK (0.93) | BTKEGFRITKLCKFLT3 | |
| SCHEMBL722562 | 1.00 | BTK (0.93) | BTKEGFRITKLCKFLT3 | |
| SCHEMBL202459 | 0.96 | BTK (1.00) | BTKEGFRITKLCKFLT3 | |
| SCHEMBL203607 | 0.96 | BTK (1.00) | BTKEGFRITKLCKFLT3 | |
| SCHEMBL15488805 | 0.96 | BTK (1.00) | BTKEGFRITKLCKFLT3 | |
| SCHEMBL19360226 | 0.96 | BTK (1.00) | BTKEGFRITKLCKFLT3 | |
| SCHEMBL441377 | 0.95 | BTK (1.00) | BTKEGFRITKLCKFLT3 | |
| SCHEMBL410214 | 0.95 | BTK (1.00) | BTKEGFRITKLCKFLT3 | |
| SCHEMBL14575750 | 0.95 | BTK (0.84) | BTKEGFRITKLCKFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053189-A1 | BTK INHIBITORS FOR THE TREATMENT OF IMMUNE MEDIATED CONDITIONS | PHARMACYCLICS, INC. (US) | 2012-03-01 | — | — | US | claimed |
| US-20120053189-A1 | BTK INHIBITORS FOR THE TREATMENT OF IMMUNE MEDIATED CONDITIONS | PHARMACYCLICS, INC. (US) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053189-A1 | BTK INHIBITORS FOR THE TREATMENT OF IMMUNE MEDIATED CONDITIONS | BTK, SYK, LCK | BTK 1/4885EGFR 997/4885ITK 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.